DRL partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of the Sputnik V and for its distribution rights in India. The vaccine underwent a bridge trial in Indian on 1600 people.
Sputnik V has demonstrated an efficacy rate of 91.6 per cent in the interim analysis of the phase-3 trial, which included data on 19,866 volunteers in Russia, who received both the first and second doses of the vaccine. Sputnik V maintained an efficacy at 91.8 per cent even among the group of 2,144 volunteers over 60 years old, DRL claimed.
The human adenoviral vector (flu virus) based vaccine candidate is developed by the Gamaleya National Research Institute of Epidemiology and Microbiology in Russia and was registered in that country in August last year.
DRL would market the vaccine in India. It said it hopes to supply both to the government and also to the private market.On the pricing front, DRL has said it was discussing the Indian situation with RDIF. In India, vaccine makers like Serum Institute of India
have announced two separate pricings — one for the government and the other for the private market. RDIF has announced a global price of $10 per dose for the Sputnik V earlier.